Data from a consecutive series of 13 patients with stage III malignant melanoma indicate that patients with BRAFV600E-mutant marginally resectable or irresectable melanoma are able to derive clinical benefit from neoadjuvant BRAF inhibition. This approach enabled all patients to undergo surgical resection, which was macroscopically successful in all cases. A total of four patients had a complete pathological response with no viable tumour cells detected in resection specimens, and 10 patients remain free of disease after a median follow-up duration of 20 months.
References
Zippel, D. et al. Perioperative BRAF inhibitors in locally advanced stage III melanoma. J. Surg. Oncol. http://dx.doi.org/10.1002/jso.24744 (2017)
Rights and permissions
About this article
Cite this article
Sidaway, P. Neadjuvant BRAF inhibition enables resection. Nat Rev Clin Oncol 14, 524 (2017). https://doi.org/10.1038/nrclinonc.2017.106
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2017.106